Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528786 | 0.78 | GABRA1 (0.42) | L3MBTL1DPP4 | |
| SCHEMBL2525849 | 0.78 | MAPK1 (0.36) | L3MBTL1DPP4ALDH1A1MAPK1NPSR1 | |
| Hydrochloric Acid SCHEMBL2529558 | 0.77 | MAPK1 (0.35) | L3MBTL1DPP4ALDH1A1MAPK1NPSR1 | |
| SCHEMBL22349830 | 0.71 | SCN9A (0.42) | ALDH1A1 | |
| SCHEMBL2527837 | 0.71 | QPCT (0.36) | L3MBTL1ALDH1A1 | |
| SCHEMBL2525793 | 0.69 | MBOAT4 (0.34) | L3MBTL1GAAMAPK1 | |
| SCHEMBL2526431 | 0.69 | CDK4 (0.38) | L3MBTL1AMY1A | |
| SCHEMBL30203066 | 0.67 | ROCK2 (0.39) | DPP4ALDH1A1NPSR1 | |
| SCHEMBL22349825 | 0.66 | LMNA (0.46) | L3MBTL1ALDH1A1NPSR1 | |
| SCHEMBL2526791 | 0.66 | NPC1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039458-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1948666-B1 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1948666-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007061714-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061714-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
| US-20070111984-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111984-A1 | HIV integrase inhibitors | TYMP, POLN, IMPDH1 | L3MBTL1 2458/4885GAA 675/4885DPP4 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.